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The rewiring ofmetabolism in cancer is thought to result fromhyperactivation of signaling pathways
that instruct cells to grow. Sebastian et al. show that loss of the tumor suppressor SIRT6 transforms
cells by activating tumor metabolism. This occurs independently of mutations in canonical growth
signaling pathways and reveals a tumorigenic role for cancer metabolism.The metabolic requirements of cancer
cells differ from those of normal cells.
Whereas normal cells take up and utilize
nutrients to maintain homeostasis, cancer
cells reprogram metabolism to facilitate
growth and survival. For years, it was
thought that such metabolic reprogram-
ming was a consequence of tumorigen-
esis, where mutations in growth factor
signal transduction pathways activate
cellular proliferation, and that alterations
in metabolism follow to enable tumor
growth. Given the interconnectedness of
these two processes, it has been difficult
to disentangle cause from effect. In this
issue of Cell, Sebastian et al. (2012)
describe a role for SIRT6 in tumor metab-
olism in which conditional deletion of
SIRT6 activates an anabolic metabolism
program that is sufficient to promote
tumorigenesis independent of canonical
transforming events.
Alterations in glucose and glutamine
metabolism are now recognized as com-
mon features in cancer, and numerous
studies have mapped the signaling and
genetic events that enable these
phenomena. In general, the metabolic
enzymes that drive anabolic metabolism
are turned on downstream of growth
factor signal transduction pathways (Van-
der Heiden et al., 2009). Such signaling
converges on a common set of metabolic
attributes that activate nutrient uptake
and utilization in cell-building processes.
Given that transcriptional programs that
control cancer metabolism are activated
as a consequence of unregulated growthsignals, it has been difficult to ascertain
the sequence of events in tumorigenesis
and to determine the relative contribution
of metabolic reprogramming to tumori-
genesis. Very recently, several notable
examples have demonstrated a causal
role for activating metabolic adaptations
in tumorigenesis. Among these are the
genomic amplification of PHGDH, the
rate-limiting enzyme in serine biosyn-
thesis (Locasale et al., 2011; Possemato
et al., 2011), and overexpression of the
glycine metabolizing enzyme GLDC
(Zhang et al., 2012). Although both of
these enzymes concern serine/glycine
metabolism, the work from these studies
has demonstrated proof of principle that
metabolic enzymes can function in an
oncogenic role.
SIRT6 is a member of the sirtuin family
of NAD(+)-dependent deacetylases that
acts to maintain genomic stability and to
repress gene transcription (Mostoslavsky
et al., 2006). Among the genes that SIRT6
represses are a number of enzymes
involved in the homeostatic control of
glucose metabolism (Zhong et al., 2010).
Consistent with this concept, Sebastian
et al. (2012) now demonstrate that, in
both transformed and nontransformed
cells, deletion of SIRT6 promotes the
rapid uptake of glucose and its break-
down via glycolysis. This method of
metabolism is known as the Warburg
effect or aerobic glycolysis and is among
the most well-characterized features of
cancer metabolism (Vander Heiden
et al., 2009). Aerobic glycolysis is oftenCell 151, Dactivated in cancer cells by overexpres-
sion of the transcription factor HIF-1a
downstream of hyperactivated growth
pathways (Gordan et al., 2007). Similarly,
loss of the transcriptional corepressor
SIRT6 enables the direct upregulation of
select HIF-1a target genes involved in
glucose metabolism (such as Glut1,
Pfk1, Pdk1, and Ldha). Importantly,
HIF-1a is not activated directly, nor are
other pathways with more pleiotropic
effects on cellular proliferation and
survival. As such, Sebastian et al. (2012)
are able to decouple the effects of acti-
vating aerobic glycolysis on tumorigen-
esis from the more widespread effects
that occur downstream of activated
growth signaling pathways or HIF-1a
overexpression. Indeed, the activation of
aerobic glycolysis incurred upon deletion
of SIRT6 promotes tumorigenesis in
mouse models of colon cancer. More-
over, Sebastian et al. (2012) demonstrate
that inhibition of aerobic glycolysis by
short hairpin RNA (shRNA)-mediated
knockdown of PDK1 or its pharmacolog-
ical inhibition impairs SIRT6 loss-depen-
dent tumorigenesis and tumor growth.
Collectively, these results support the
idea that the reprogramming of cancer
metabolism is not merely a consequence
of transformation but that aerobic glycol-
ysis can promote transformation.
Like HIF-1a, MYC expression is also
frequently activated in cancer down-
stream of common growth factor signal
transducing pathways, and MYC acts
to drive anabolic metabolism (Gordanecember 7, 2012 ª2012 Elsevier Inc. 1155
Figure 1. Loss of SIRT6-Mediated Sup-
pression of Cancer Metabolism Promotes
Tumorigenesis
(A) The deacetylase SIRT6 acts as a corepressor of
HIF-1a- and MYC-dependent cancer metabolism
but does not globally repress HIF-1a or MYC
transcription.
(B) SIRT6 inhibits aerobic glycolysis, anabolic gluta-
mine metabolism, and ribosome biogenesis. To-
gether, activation of these metabolic pathways
promotes tumorigenesisand tumorgrowth. Inhibition
of aerobic glycolysis by knockdown of PDK1 using
short hairpin RNA (shPDK1) or pharmacological
inhibition with dichloroacetate (DCA) blocks the
tumorigenic activity of SIRT6 loss.
1156 Cell 151, December 7, 2012 ª2012 Elseet al., 2007). The metabolic output of
MYC activation is highly tissue- and onco-
gene-context dependent. For example,
MYC can activate pathways involved in
anabolic glucose (Ying et al., 2012) or
glutamine metabolism (Wise et al., 2008).
Sebastian et al. (2012) find that loss of
SIRT6 also leads to the activation of
a distinct subset of the MYC-dependent
genes involved in ribosomal biogenesis
and glutamine metabolism. Strikingly,
this again does not occur downstream of
growth factor signaling pathway activa-
tion but rather occurs as a result of loss
of the corepressor function of SIRT6.
Thus, the consequence of SIRT6 deletion
is not an increase in HIF-1a orMYC levels,
but rather an enhancement in the ability of
these transcription factors to drive ex-
pression of specific target genes. More-
over, knockdown of MYC in the context
of SIRT6 deletion dramatically impairs
tumorigenesis and tumor growth. Collec-
tively, this study demonstrates that loss
of SIRT6 corepressor activity directly
engages aerobic glycolysis, ribosomal
biogenesis, and anabolic glutamine
metabolism independent of mutations in
growth factor signaling pathways. Activa-
tion of each of these distinct metabolic
components is necessary for tumorigen-
esis, and together, this metabolic reprog-
ramming is sufficient to transform cells
(Figure 1).
Although this body of work provides
convincing evidence for a tumorigenic
role of metabolic reprogramming, it also
raises several fascinating questions. The
first concerns the role of NAD+/NADH
redox balance. The metabolic activity of
SIRT6 requires the cofactor NAD+.
Glycolysis drives the consumption of
NAD+ by GAPDH and may thereby impair
SIRT6 activity due to limiting substrate.
Thus, the activation of glycolysis may
function in a manner parallel to SIRT6
loss by impairing SIRT6 activity, driving
aerobic glycolysis in a feed-forward
fashion. In addition, SIRT6 plays a role in
maintaining genome stability (Mostoslav-
sky et al., 2006). Although Sebastian
et al. (2012) show that SIRT6 overexpres-
sion can revert the tumorigenic pheno-
type of SIRT6 deletion (to argue thatvier Inc.irreversible genomic mutations are not
a contributing factor), it is unclear whether
SIRT6 overexpression affects cell trans-
formation in the same fashion as SIRT6
deletion. It will be interesting to see how
these phenomena influence the tumori-
genic role of SIRT6 and the rewiring of
cancer metabolism.ACKNOWLEDGMENTS
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